SG11202113244UA - Pyrrolidine compounds - Google Patents

Pyrrolidine compounds

Info

Publication number
SG11202113244UA
SG11202113244UA SG11202113244UA SG11202113244UA SG11202113244UA SG 11202113244U A SG11202113244U A SG 11202113244UA SG 11202113244U A SG11202113244U A SG 11202113244UA SG 11202113244U A SG11202113244U A SG 11202113244UA SG 11202113244U A SG11202113244U A SG 11202113244UA
Authority
SG
Singapore
Prior art keywords
compound
mmol
pharmaceutically acceptable
tert
butyl
Prior art date
Application number
SG11202113244UA
Other languages
English (en)
Inventor
Blanco Celia Lafuente
Buezo Nuria Diaz
Perez Jose Antonio Martinez
Gil Gema Consuelo Sanz
Soler Julian Priego
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11202113244UA publication Critical patent/SG11202113244UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG11202113244UA 2019-06-07 2020-06-03 Pyrrolidine compounds SG11202113244UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382477 2019-06-07
PCT/US2020/035825 WO2020247429A1 (en) 2019-06-07 2020-06-03 Pyrrolidine compounds

Publications (1)

Publication Number Publication Date
SG11202113244UA true SG11202113244UA (en) 2021-12-30

Family

ID=66821161

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113244UA SG11202113244UA (en) 2019-06-07 2020-06-03 Pyrrolidine compounds

Country Status (25)

Country Link
US (3) US11286249B2 (https=)
EP (1) EP3980409A1 (https=)
JP (4) JP6940717B2 (https=)
KR (3) KR102629923B1 (https=)
CN (1) CN114008021B (https=)
AU (1) AU2020287599B2 (https=)
BR (1) BR112021023347A2 (https=)
CL (1) CL2021003202A1 (https=)
CO (1) CO2021016295A2 (https=)
CR (1) CR20210602A (https=)
DO (1) DOP2021000254A (https=)
EA (1) EA202193007A1 (https=)
EC (1) ECSP21088515A (https=)
IL (2) IL288174B2 (https=)
JO (1) JOP20210319B1 (https=)
MA (1) MA56115A (https=)
MX (2) MX2021014913A (https=)
MY (1) MY200810A (https=)
PE (1) PE20220134A1 (https=)
PH (1) PH12021553062A1 (https=)
SA (1) SA521431048B1 (https=)
SG (1) SG11202113244UA (https=)
UA (1) UA128540C2 (https=)
WO (1) WO2020247429A1 (https=)
ZA (1) ZA202109251B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023078333A1 (zh) 2021-11-03 2023-05-11 上海拓界生物医药科技有限公司 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途
WO2023146785A1 (en) 2022-01-26 2023-08-03 Eli Lilly And Company Pyrrolidine compounds
CN120787221A (zh) 2023-03-24 2025-10-14 上海京新生物医药有限公司 一种环状胺衍生物及其组合物与应用
CN119894882A (zh) * 2023-04-21 2025-04-25 深圳信立泰药业股份有限公司 一种叔胺类化合物及其制备方法和医药用途
WO2024230805A1 (zh) 2023-05-11 2024-11-14 江苏恒瑞医药股份有限公司 一种脂蛋白化合物晶型及其制备方法
TW202509024A (zh) 2023-05-19 2025-03-01 大陸商深圳信立泰藥業股份有限公司 一種磺醯胺類化合物及其製備方法和醫藥用途
EP4734986A1 (en) 2023-06-30 2026-05-06 Eli Lilly and Company Therapeutic uses and doses of lp(a) disrupter compounds
WO2025024216A1 (en) 2023-07-21 2025-01-30 Eli Lilly And Company PYRROLIDINE COMPOUNDS Lp(a) LOWERING ACTIVITY
WO2025024218A1 (en) 2023-07-21 2025-01-30 Eli Lilly And Company PYRROLIDINE COMPOUNDS WITH Lp(a) LOWERING ACTIVITY
WO2025024210A1 (en) 2023-07-21 2025-01-30 Eli Lilly And Company Piperidine, morpholine and tetrahydro-pyridazine compounds with lp(a) lowering activity
CN121548568A (zh) 2023-07-21 2026-02-17 伊莱利利公司 具有Lp(a)降低活性的哌啶化合物
CN119490445A (zh) * 2023-08-15 2025-02-21 深圳信立泰药业股份有限公司 一种酰基类化合物及其制备方法和医药用途
US20250179055A1 (en) * 2023-11-17 2025-06-05 Innovstone Therapeutics Limited Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof
WO2025108255A1 (zh) * 2023-11-20 2025-05-30 上海齐鲁制药研究中心有限公司 一种多环类衍生物、其制备方法和应用
WO2025237188A1 (zh) * 2024-05-14 2025-11-20 石家庄以岭药业股份有限公司 一种LP(a)抑制剂化合物及其应用
WO2025255324A1 (en) * 2024-06-06 2025-12-11 Lapis Therapeutics, Inc. Inhibitors of lipoprotein(a) assembly
WO2026061518A1 (zh) * 2024-09-23 2026-03-26 上海京新生物医药有限公司 一种环状胺衍生物的固体形式、制备方法及药物组合物
JP7850336B1 (ja) 2024-11-14 2026-04-22 イーライ リリー アンド カンパニー Lp(a)阻害剤化合物を含む経口組成物
CN121609698A (zh) * 2026-01-30 2026-03-06 山东京新药业有限公司 一种莫伐培林及中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685325B1 (fr) * 1991-12-20 1994-02-04 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US7371777B2 (en) 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
AU2003300438A1 (en) * 2003-12-24 2005-08-03 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
JP2007525408A (ja) * 2003-12-24 2007-09-06 エスペリオン セラピューティクス,インコーポレイテッド コレステロール管理および関連使用のためのケトン化合物および組成物
CA2694362A1 (en) 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
KR20180086259A (ko) 2016-02-03 2018-07-30 상하이 하이옌 파마슈티컬 테크놀로지 컴퍼니, 리미티드 헤테로 고리로 치환된 n-설포닐벤즈아미드 유도체, 이의 제조 방법과 약학적 용도
CN112321475B (zh) 2020-11-13 2022-06-10 四川大学 一种γ-氨基酸类似物及其合成方法

Also Published As

Publication number Publication date
BR112021023347A2 (pt) 2022-04-12
UA128540C2 (uk) 2024-08-07
AU2020287599B2 (en) 2023-10-19
JP7658014B2 (ja) 2025-04-07
IL288174A (en) 2022-01-01
JP7508422B2 (ja) 2024-07-01
JOP20210319B1 (ar) 2024-12-22
JP6940717B2 (ja) 2021-09-29
KR102477481B1 (ko) 2022-12-15
CN114008021A (zh) 2022-02-01
KR20220018494A (ko) 2022-02-15
JOP20210319A1 (ar) 2023-01-30
IL321703B1 (en) 2026-04-01
CN114008021B (zh) 2024-11-05
DOP2021000254A (es) 2022-01-16
EP3980409A1 (en) 2022-04-13
MX2025001789A (es) 2025-03-07
JP2025098178A (ja) 2025-07-01
US11286249B2 (en) 2022-03-29
US20260055086A1 (en) 2026-02-26
KR20230004890A (ko) 2023-01-06
CL2021003202A1 (es) 2022-09-09
PH12021553062A1 (en) 2022-08-15
CA3140869A1 (en) 2020-12-10
AU2020287599A1 (en) 2022-01-06
MA56115A (fr) 2022-04-13
IL288174B1 (en) 2025-08-01
MX2021014913A (es) 2022-01-18
EA202193007A1 (ru) 2022-03-25
KR102629923B1 (ko) 2024-01-30
SA521431048B1 (ar) 2024-04-28
CR20210602A (es) 2022-01-06
JP2024123111A (ja) 2024-09-10
US12441714B2 (en) 2025-10-14
IL288174B2 (en) 2025-12-01
KR102720992B1 (ko) 2024-10-24
IL321703A (en) 2025-08-01
US20210253559A1 (en) 2021-08-19
NZ782992A (en) 2025-02-28
CO2021016295A2 (es) 2021-12-10
JP2021191784A (ja) 2021-12-16
US20220169636A1 (en) 2022-06-02
WO2020247429A1 (en) 2020-12-10
ECSP21088515A (es) 2022-01-31
JP2021524498A (ja) 2021-09-13
KR20240014618A (ko) 2024-02-01
ZA202109251B (en) 2024-04-24
PE20220134A1 (es) 2022-01-27
MY200810A (en) 2024-01-16

Similar Documents

Publication Publication Date Title
JP7658014B2 (ja) ピロリジン化合物
EA017648B1 (ru) 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
JP5355551B2 (ja) キノロン化合物及び医薬組成物
WO2010146488A1 (en) Bicyclic and tricyclic compounds as kat ii inhibitors
JP2020505440A (ja) Hdac6選択的阻害剤およびその製造方法と使用
JP5769504B2 (ja) 医薬
AU2018228555A1 (en) Azetidine derivative
CA3140869C (en) Pyrrolidine compounds
JP7716980B2 (ja) エストロゲン受容体拮抗剤
EA045074B1 (ru) Соединения пирролидина
AU2024298640A1 (en) Piperidine Compounds with Lp(a) Lowering Activity
WO2025024216A1 (en) PYRROLIDINE COMPOUNDS Lp(a) LOWERING ACTIVITY